文献速递前列腺癌

根治性前列腺切除术后10年无病间期前列腺癌患者生化复发与转移风险

Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval.
PubMed 文献 · Eur Urol Oncol · 2024-09-20

在五个欧洲三级中心回顾性纳入1992至2012年行根治性前列腺切除术且术后120个月内无生化复发的4639例前列腺癌患者,随访中位147个月,243例(5.2%)出现晚期生化复发,其中23例(9.5%)随后发生转移进展。pT3a、pT3b、病理Gleason评分3+4、≥4+3、手术切缘R1/Rx及pNx为生化复发的独立预测因素。

要点

  • 术后10年无生化复发者中仍有约5.2%出现晚期生化复发。
  • pT3a(HR 1.46)、pT3b(HR 2.42)、pGS 3+4(HR 1.71)、pGS≥4+3(HR 2.47)、R1/Rx(HR 1.72)为独立预测因素。
  • pT2期且pGS≤3+4者晚期生化复发及转移(0.3%)率极低,作者认为该队列可考虑放弃10年后的随访。

核心结论

  • 根治性前列腺切除术后至少10年无生化复发的前列腺癌患者中,约二十分之一仍会出现晚期生化复发。
  • pT2期且pGS≤3+4患者晚期生化复发及随后转移(0.3%)率极低,作者认为在该队列中放弃10年无事件后的随访是合理的。

研究设计与样本

  • 回顾性识别五个欧洲三级中心1992至2012年行根治性前列腺切除术且术后120个月内无生化复发的4639例前列腺癌患者。
  • 生化复发定义为连续两次PSA≥0.2 ng/ml。
  • 采用Kaplan-Meier法和Cox回归模型分析生化复发与患者或肿瘤特征的关系。

主要发现

  • 中位随访147个月,243例(5.2%)出现生化复发。
  • 243例生化复发患者中,23例(9.5%)随后发生转移进展。
  • Kaplan-Meier模型中,无生化复发生存率因晚期肿瘤状态而异。
  • 多变量Cox回归中,pT3a(HR 1.46)、pT3b(HR 2.42)、pGS 3+4(HR 1.71)、pGS≥4+3(HR 2.47)、R1/Rx(HR 1.72)、pNx(HR 0.72)为生化复发的独立预测因素(均p<0.05)。
  • 年龄、诊断时PSA及手术年份未能成为生化复发的独立预测因素。

关键数值与推荐

  • 生化复发定义:连续两次PSA≥0.2 ng/ml。
  • 生化复发独立预测因素HR:pT3a 1.46、pT3b 2.42、pGS 3+4 1.71、pGS≥4+3 2.47、R1/Rx 1.72、pNx 0.72(均p<0.05)。
  • pT2期且pGS≤3+4患者晚期生化复发及转移率为0.3%。

临床怎么用

  • 作者认为,对于pT2期且pGS≤3+4、术后10年无生化复发的患者,放弃10年后的随访是合理的。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA) testing is used to follow up prostate cancer (PCa) patients treated with radical prostatectomy (RP). Research on PSA thresholds for identifying PCa patients with biochemical recurrence (BCR) who are at a higher risk of progression yielded inconclusive results. This study aims to investigate the risk of late BCR in PCa patients treated with RP and long postoperative (120 mo) undetectable PSA follow-up, and to identify prognostic factors for late BCR within this patient cohort. METHODS: PCa patients treated with curative RP (1992-2012) and free of BCR during the first 120 mo following RP were retrospectively identified within five European tertiary centers; BCR was defined as two consecutive PSA values of ≥0.2 ng/ml. Kaplan-Meier and Cox regression models tested for an association between BCR and patient or tumor characteristics. KEY FINDINGS AND LIMITATIONS: The study cohort consisted of 4639 patients, of whom 243 (5.2%) developed BCR at a medium follow-up of 147 mo. Of those with BCR, 23 (9.5%) subsequently developed metastatic progression. In Kaplan-Meier models, BCR-free survival differed according to advanced tumor status. In multivariable Cox regression models, pT stage (pT3a: hazard ratio [HR]: 1.46; pT3b: HR: 2.42), pathological Gleason score (pGS 3 + 4: HR: 1.71; pGS ≥4 + 3: HR: 2.47), surgical margin (R1/Rx: HR: 1.72), and pNx stage (pNx: HR: 0.72) represented independent predictors for BCR (all p < 0.05). Conversely, age, PSA at diagnosis, and year of surgery failed to achieve independent predictor status for BCR. CONCLUSIONS AND CLINICAL IMPLICATIONS: Among PCa patients with an uneventful follow-up of at least 10 yr after RP, still one in 20 patients subsequently develop late BCR. Nevertheless, late BCR and subsequent progression to metastasis (0.3%) rates in patients with pT2 stage and pGS ≤3 + 4 were strikingly low, implicating that abandoning follow-up beyond an uneventful period of 10 yr is justifiable within this cohort of patients. PATIENT SUMMARY: In this study, prostate cancer patients treated with a radical prostatectomy and at least 10 yr of uneventful prostate-specific antigen testing were identified within five European centers. Relying on these patients, the rate of subsequent late biochemical recurrence was calculated and risk factors were identified for biochemical recurrence following 10 yr of uneventful prostate-specific antigen testing.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hoeh B, Preisser F, Zattoni F, et al. Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval. Eur Urol Oncol. 2024. PMID: 39306583. doi:10.1016/j.euo.2024.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。